177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy.
Saved in:
| Title: | 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. |
|---|---|
| Authors: | John N; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Pathmanandavel S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Crumbaker M; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Counter W; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Ho B; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Yam AO; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Wilson P; MIM Software, Inc., Cleveland, Ohio; and., Niman R; MIM Software, Inc., Cleveland, Ohio; and., Ayers M; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Poole A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Hickey A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Agrawal S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Perkins G; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Kallinen A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Eslick E; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Joshua AM; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Emmett L; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia; louise.emmett@svha.org.au.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Mar; Vol. 64 (3), pp. 410-415. Date of Electronic Publication: 2022 Sep 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
